Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $106.73M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.48M
Average 0.15M
FHTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $2.38M fell 11.5% year over year, behind the +42.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 6.3% from the prior quarter.
Context
- Stock-based compensation amounted to 33.6% of revenue in FY2025, down 19.0 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -11.5% toward the trailing-twelve-month pace of +42.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.4M USD
- Year-over-year change
- -12.6%
- 4-year CAGR
- +5.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.4M | -12.6% |
| FY2024 | 2024-12-31 | 11.89M | -26.5% |
| FY2023 | 2023-12-31 | 16.19M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 8.38M | — |
Stock-Based Compensation vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 stock-based compensation of $7.36M is the 8th largest of the 11 companies compared; the peer median is $9.75M.
- Its year-over-year change of +42.2% is the 3rd highest of 11, against a peer median of -28.1%.
- Stock-based compensation amounts to 26.1% of revenue for FHTX, versus a peer median of 50.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.07M | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
ZURAZura Bio Limited | LTM Mar 2026 | $11.32M | -37.2% | +233.0% | — |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $9.07M | -23.3% | -16.5% | 4.2% | |
| LTM Mar 2026 | $8.17M | -33.3% | -9.2% | 59.0% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $6.82M | +13.6% | +50.8% | — |
| LTM Mar 2026 | $5.08M | +64.3% | -10.8% | 7.1% | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding FHTX) | $9.75M | -28.1% | -6.0% | 50.9% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Depreciation & Amortization | 3.23M | 7.9M | 3.45M | 3.12M | 3.33M |
| Deferred Income Tax | 1.41M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.38M | 0 | 16.19M | 11.89M | 10.4M |
| Change in Working Capital | 33.44M | 281.55M | (41.88M) | (32.27M) | (32.14M) |
| Accounts Receivables | (300M) | 300M | 0 | 0 | 0 |
| Inventory | (3.17M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 135K | 1.61M | 846K | (2.48M) | 481K |
| Other Working Capital | 336.48M | (20.07M) | (42.73M) | (29.79M) | (32.62M) |
| Other Non-Cash Items | 4.61M | 13.05M | 2.56M | 3.47M | 6.59M |
| Operating Cash Flow | (50.25M) | 193.61M | (118.11M) | (100.41M) | (86.1M) |
| Capital Expenditures | (3.31M) | (1.21M) | (1.22M) | (906K) | (50K) |
| Acquisitions (Net) | (39.49M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (99.98M) | (409.35M) | (73.9M) | (261.47M) | (131.25M) |
| Sales of Investments | 139.47M | 166.23M | 219.58M | 232.47M | 243.34M |
| Other Investing Activities | 39.49M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 36.17M | (244.32M) | 144.45M | (29.9M) | 112.04M |
| Debt Repayment | (21.21M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 42.21M | 1.76M | 0 | 103.4M | 1.02M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.42M | 0 | 1.78M | 2.03M | 0 |
| Financing Cash Flow | 22.42M | 1.76M | 1.78M | 105.43M | 1.02M |
| Effect of Forex Changes | 0 | 25K | 0 | 0 | 0 |
| Net Change in Cash | 8.34M | (48.92M) | 28.12M | (24.88M) | 26.96M |
| Free Cash Flow | (53.56M) | 192.4M | (119.33M) | (101.31M) | (86.15M) |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.